BaselPelacarsen failed to prevent heart attacks or strokes.
One in five people worldwide carry the risk factor it targeted, untreated.
The drug slashed Lp(a) levels sharply in earlier trials, but lower levels did not translate into fewer cardiac events.
No therapy has yet proven that lowering Lp(a) prevents heart attacks.
How each outlet framed it
- STAT
- isolates failure mode—pelacarsen cut Lp(a) in earlier trials but failed Phase 3 on cardiovascular outcomes, leaving field to Amgen/Eli Lilly
Sources: STAT